Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials

被引:4
|
作者
Salazar, Ana S. [1 ]
Rakhmankulova, Malika [1 ]
Simon, Laura E. [2 ]
Toriola, Adetunji T. [1 ]
机构
[1] Washington Univ, Dept Surg, Div Publ Hlth Sci, Sch Med, St Louis, MO 63110 USA
[2] Washington Univ, Bernard Becker Med Lib, Sch Med, St Louis, MO 63110 USA
基金
美国国家卫生研究院;
关键词
CANCER RISK; YOUNG-WOMEN; ASSOCIATION; MENOPAUSE; TAMOXIFEN; THERAPY; TIME;
D O I
10.1093/jncics/pkaa125
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Higher mammographic breast density (MBD) is associated with an increased risk of breast cancer when compared with lower MBD, especially in premenopausal women. However, little is known about the effectiveness of chemoprevention agents in reducing MBD in premenopausal women without a history of breast cancer. Findings from this review should provide insight on how to target MBD in breast cancer prevention in premenopausal women with dense breasts. Methods: We searched 9 electronic databases for clinical trials in English, Spanish, French, or German published until January 2020. Articles evaluating the association of pharmacological agents and MBD were included. Data were extracted on methods, type and dose of intervention, outcomes, side effects, and follow up. Quality of the studies was assessed using the US Preventive Services Task Force criteria. Results: We identified 7 clinical trials evaluating the associations of 6 chemoprevention agents with changes in MBD in premenopausal women without history of breast cancer. The studies evaluated selective estrogen-receptor modulators (n=1); gonadotropin-releasing hormone agonists (n=2); isoflavones (n=1); vitamin D (n=1); and Boswellia, betaine, and mayo-inositol compound (n=1). Hormonal interventions were associated with net reductions in percent density (tamoxifen [13.4%], leuprolide acetate [8.9%], and goserelin [2.7%]), whereas nonhormonal (vitamin D and isoflavone) interventions were not. However, MBD returned to preintervention baseline levels after cessation of gonadotropin-releasing hormone agonists. Conclusions: A limited number of chemoprevention agents have been shown to reduce MBD in premenopausal women. Identification of new and well-tolerated chemoprevention agents targeting MBD and larger studies to confirm agents that have been studied in small trials are urgent priorities for primary breast cancer prevention in premenopausal women with dense breasts.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Associations of Vitamins and Related Cofactor Metabolites with Mammographic Breast Density in Premenopausal Women
    Matthew, Kayode A.
    Getz, Kayla R.
    Jeon, Myung Sik
    Luo, Chongliang
    Luo, Jingqin
    Toriola, Adetunji
    JOURNAL OF NUTRITION, 2024, 154 (02): : 424 - 434
  • [32] Vitamin D and mammographic breast density: a systematic review
    Lusine Yaghjyan
    Graham A. Colditz
    Bettina Drake
    Cancer Causes & Control, 2012, 23 : 1 - 13
  • [33] Physical activity and mammographic breast density: a systematic review
    Lusine Yaghjyan
    Graham A. Colditz
    Kathleen Wolin
    Breast Cancer Research and Treatment, 2012, 135 : 367 - 380
  • [34] Vitamin D and mammographic breast density: a systematic review
    Yaghjyan, Lusine
    Colditz, Graham A.
    Drake, Bettina
    CANCER CAUSES & CONTROL, 2012, 23 (01) : 1 - 13
  • [35] Physical activity and mammographic breast density: a systematic review
    Yaghjyan, Lusine
    Colditz, Graham A.
    Wolin, Kathleen
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 135 (02) : 367 - 380
  • [36] Association of bone mineral density and mammographic breast density in premenopausal and postmenopausal Malaysian women: study on women with and without breast cancer
    Zain, Norhayati Mohd
    Seriramulu, Vengkatha Priya
    Chelliah, Kanaga Kumari
    Soin, Norhayati
    Arasaratnam, Shantini
    2016 INTERNATIONAL CONFERENCE ON BIO-ENGINEERING FOR SMART TECHNOLOGIES (BIOSMART), 2016,
  • [37] Fertility Drug Use and Mammographic Breast Density in a Mammography Screening Cohort of Premenopausal Women
    Sprague, Brian L.
    Trentham-Dietz, Amy
    Terry, Mary Beth
    Nichols, Hazel B.
    Bersch, Andrew J.
    Buist, Diana S. M.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (11) : 3128 - 3133
  • [38] Metabolic Syndrome and Mammographic Density in Premenopausal Chilean Women
    Martinez-Arroyo, Angela
    Moreno-Macias, Hortensia
    Pereira Scalabrino, Ana
    Luisa Garmendia, Maria
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2017, 69 (02): : 254 - 260
  • [39] Influence of factors on mammographic density in premenopausal Chinese women
    Yang, Yaping
    Liu, Jieqiong
    Gu, Ran
    Hu, Yue
    Liu, Fengtao
    Yun, Miaomiao
    Xiao, Qiaozhen
    Wu, Mei
    Liu, Qiang
    Su, Fengxi
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2016, 25 (04) : 306 - 311
  • [40] Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+HER2-breast cancer
    Patterson-Lomba, Oscar
    Dalal, Anand A.
    Ayyagari, Rajeev
    Liu, Olivia
    Dervishi, Eni
    Platt, Emma
    Chandiwana, David
    O'Shaughnessy, Joyce A.
    BREAST JOURNAL, 2019, 25 (05): : 880 - 888